Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Nurix Therapeutics's share price for the quarter that ended in Feb. 2024 was $12.35. Nurix Therapeutics's Shares Outstanding (EOP) for the quarter that ended in Feb. 2024 was 49.14 Mil. Therefore, Nurix Therapeutics's market cap for the quarter that ended in Feb. 2024 was $606.84 Mil.
Nurix Therapeutics's quarterly market cap
declined
from Aug. 2023 ($412.28 Mil) to Nov. 2023 ($303.03 Mil) but then
increased
from Nov. 2023 ($303.03 Mil) to Feb. 2024 ($606.84 Mil).
Nurix Therapeutics's annual market cap
declined
from Nov. 2021 ($1,287.23 Mil) to Nov. 2022 ($584.46 Mil) and
declined
from Nov. 2022 ($584.46 Mil) to Nov. 2023 ($303.03 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Nurix Therapeutics's Enterprise Value for Today is $636.44 Mil.
Nurix Therapeutics Market Cap Historical Data
The historical data trend for Nurix Therapeutics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Nurix Therapeutics's Market Cap
For the Biotechnology subindustry, Nurix Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nurix Therapeutics's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nurix Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Nurix Therapeutics's Market Cap falls into.
Nurix Therapeutics Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Nurix Therapeutics's Market Cap for the fiscal year that ended in Nov. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nurix Therapeutics (NAS:NRIX) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Nurix Therapeutics Market Cap Related Terms
Thank you for viewing the detailed overview of Nurix Therapeutics's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Nurix Therapeutics (Nurix Therapeutics) Business Description
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NRIX has been successfully added to your 